A Phase 1 interventional study of Crizotinib and Pembrolizumab in ALK-positive Advanced NSCLC, sponsored by Pfizer. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-01.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by enrollment, is one of 4 that started in 2015, is one of 5 in phase 1, and was the 13th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 122nd largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2015, is one of 56 in phase 1, and was the 68th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.
The patients will be screened for up to 28 days before they start treatment to determine if they meet eligibility criteria. The screening procedures will include physical examination, blood work and radiological scans.
In the dose finding phase, patients who meet eligibility criteria will receive crizotinib at the dose level assigned that will be taken on daily basis and pembrolizumab 200 mg intravenous infusion every 3 weeks.
Once a Crizotinib dose level is decided, the dose expansion cohort will start enrolling patients who meet eligibility criteria.
All patients will be followed up every three weeks. Blood samples will be drawn to test for safety and tumor activities and radiological scans will be performed on certain timepoints to determine the antitumor activities.
There will be a quality of life questionnaire administered at certain time points during the study.
The study will have a quality assurance plan that addresses data validation and registry procedures. There is a plan to visit the investigator site for routine monitoring and auditing.
The team will conduct source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms, or interactive voice response systems).
The study will also include a statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives of this study, as specified in the study protocol or statistical plan.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 9 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
Drug: Crizotinib · Drug: Pembrolizumab
To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
Number of Participants With Dose-limiting Toxicity (DLT)
Dose-limiting toxicity (DLT) was defined as any of the following adverse events (AEs) occurring in the first 2 cycles of treatment (6 weeks) which were attributable to crizotinib, pembrolizumab or both: hematologic toxicities including Grade 4 neutropenia, febrile neutropenia, Grade greater than or equal to (\>=) 3 neutropenic infection, Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; non-hematologic toxicities including Grade \>=3 toxicities (non-laboratory), Grade \>=3 nausea, vomiting, or diarrhea despite maximal therapy, non-hematologic Grade \>=3 laboratory value if medical intervention was required to treat the participant or the abnormality led to hospitalization; inability to complete at least 80 percent of the first 2-cycle doses of crizotinib or both infusions of pembrolizumab within the DLT observation period due to treatment-related toxicity. Grade was based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version 4.03.
Time frame: 6 weeks
Number of Participants With Treatment-Emergent Adverse Events
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: 2 years
Objective Response Rate (ORR)
ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-progressive disease (PD) or not evaluated, and no new lesions. For target lesions, CR: complete disappearance of all target lesions; PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be non-pathological in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.
Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Duration of Response
Duration of Response (DR) was defined as the time from first documentation of objective tumor response (CR or PR) that was subsequently confirmed, to the first documentation of objective tumor progression or to death on study due to any cause, whichever occurred first.
Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Time to Tumor Response
Time to Tumor Response (TTR) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.
Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
Progression Free Survival
Progression Free Survival (PFS) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor progression or death on-study due to any cause, whichever occurred first. For participants who did not have documented objective progression during the study or were alive at last contact, the date of last contact was used.
Time frame: Baseline, Week 9 and every 6 weeks thereafter, for about 2 years
6-Month, 12-Month and 18-Month Progression Free Survival Probabilities
PFS probabilities were defined as the probability of being alive and progression free at 6, 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.
Time frame: Month 6, Month 12, and Month 18
Overall Survival
Overall Survival (OS) was defined as the time from the first dose of crizotinib or pembrolizumab to the date of death due to any cause. For participants who were alive at last contact, the date of last contact was used.
Time frame: Day 1 to end of study (for about 2 years)
12-Month and 18-Month Overall Survival Probabilities
OS probabilities were defined as the probability of being alive at 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.
Time frame: Month 12 and Month 18
Number of Participants With Maximum Grade in Laboratory Hematology Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment
Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, and absolute basophils. Hematology test results were graded by NCI CTCAE version 4.03.
Time frame: 2 years
Number of Participants With Maximum Grade in Laboratory Chemistry Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment
Chemistry evaluation included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate, thyroid function tests including thyroid-stimulating hormone, T3 and free T4. Chemistry test results were graded by NCI CTCAE version 4.03.
Time frame: 2 years
Plasma Concentration Summary of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Plasma Concentration Summary of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Time to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Time to Maximum Plasma Concentration (Tmax) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Apparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib + Pembrolizumab" Group
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Apparent Plasma Clearance (CL/F) of Crizotinib for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Plasma Concentration Summary of PF-06260182 for "Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Plasma Concentration Summary of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28 to 35 days after the last dose of study treatment)
Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for "Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab" Group
PF-06260182 is a metabolite of crizotinib.
Time frame: Pre-dose, and 1, 2, 4, 6 and 8 hours post-dose on Day 15 of monotherapy and on Day 1 of Cycle 6; prior to crizotinib morning dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and at the End of Treatment visit (28-35 days after the last dose of study treatment)
Serum Concentration of Pembrolizumab
Time frame: Prior to and at end of pembrolizumab infusion, 120 hours and 336 hours post Day 1 dosing of Cycle 1; pre-dose on Day 1 of Cycles 2, 4,6, 8, 12 and 16; end of Day 1 dosing of Cycle 8; End of Treatment visit
Number of Participants With Programmed Death Receptor-1 Ligand-1 (PD-L1) Expression Level Meeting Pre-defined Criteria
Archived formalin-fixed, paraffin-embedded tumor issue block was collected at screening. PD-L1 assessment was performed using immunohistochemistry. A sample was considered negative if tumor proportion score was less than 1%; positive if tumor proportion score was greater than or equal to 1%; strong positive if tumor proportion score was greater than or equal to 50%.
Time frame: Screening
| Milestone | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Started | 2 | 7 |
| Completed | 0 | 0 |
| Not completed | 2 | 7 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Dose-limiting toxicity (DLT) was defined as any of the following adverse events (AEs) occurring in the first 2 cycles of treatment (6 weeks) which were attributable to crizotinib, pembrolizumab or both: hematologic toxicities including Grade 4 neutropenia, febrile neutropenia, Grade greater than or equal to (\>=) 3 neutropenic infection, Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; non-hematologic toxicities including Grade \>=3 toxicities (non-laboratory), Grade \>=3 nausea, vomiting, or diarrhea despite maximal therapy, non-hematologic Grade \>=3 laboratory value if medical intervention was required to treat the participant or the abnormality led to hospitalization; inability to complete at least 80 percent of the first 2-cycle doses of crizotinib or both infusions of pembrolizumab within the DLT observation period due to treatment-related toxicity. Grade was based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version 4.03.
| Participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Number of Participants With Dose-limiting Toxicity (DLT) | 2 | 2 |
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| All-causality AE | 2 | 7 |
| All-causality SAE | 2 | 1 |
| Crizotinib-related AE | 2 | 7 |
| Crizotinib-related SAE | 0 | 0 |
| Pembrolizumab-related AE | 2 | 6 |
| Pembrolizumab-related SAE | 2 | 1 |
| Grade 1 all-causality AE | 0 | 1 |
| Grade 2 all-causality AE | 0 | 2 |
| Grade 3 all-causality AE | 0 | 4 |
| Grade 4 all-causality AE | 1 | 0 |
| Grade 5 all-causality AE | 1 | 0 |
ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-progressive disease (PD) or not evaluated, and no new lesions. For target lesions, CR: complete disappearance of all target lesions; PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be non-pathological in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.
| percentage of participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Objective Response Rate (ORR) | 50 | 57.1 |
Duration of Response (DR) was defined as the time from first documentation of objective tumor response (CR or PR) that was subsequently confirmed, to the first documentation of objective tumor progression or to death on study due to any cause, whichever occurred first.
| days | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Duration of Response | 85 (85 to 85) | 242 (126 to 339) |
Time to Tumor Response (TTR) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.
| days | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Time to Tumor Response | 57 (57 to 57) | 83 (77 to 87) |
Progression Free Survival (PFS) was defined as the time from the first dose of crizotinib or pembrolizumab to the first documentation of objective tumor progression or death on-study due to any cause, whichever occurred first. For participants who did not have documented objective progression during the study or were alive at last contact, the date of last contact was used.
| days | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Progression Free Survival | 131.5 (122 to 141) | 211 (1 to 418) |
PFS probabilities were defined as the probability of being alive and progression free at 6, 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.
No measurements were reported for this outcome.
Overall Survival (OS) was defined as the time from the first dose of crizotinib or pembrolizumab to the date of death due to any cause. For participants who were alive at last contact, the date of last contact was used.
| days | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Overall Survival | 452.5 (122 to 783) | 428 (272 to 730) |
OS probabilities were defined as the probability of being alive at 12 and 18 months after the date of first dose based on the Kaplan Meier estimate.
No measurements were reported for this outcome.
Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, and absolute basophils. Hematology test results were graded by NCI CTCAE version 4.03.
| Participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Anemia | 0 | 0 |
| Hemoglobin increased | 0 | 0 |
| Lymphocyte count increased | 0 | 0 |
| Lymphopenia | 0 | 2 |
| Absolute neutrophils | 0 | 0 |
| platelets | 0 | 0 |
| White blood cells | 0 | 0 |
Chemistry evaluation included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate, thyroid function tests including thyroid-stimulating hormone, T3 and free T4. Chemistry test results were graded by NCI CTCAE version 4.03.
| Participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Alanine aminotransferase | 1 | 3 |
| Alkaline phosphatase | 0 | 0 |
| Aspartate aminotransferase | 1 | 1 |
| Total bilirubin | 0 | 0 |
| Creatine kinase | 0 | 0 |
| Creatinine | 0 | 0 |
| Gamma-glutamyl transferase | 0 | 0 |
| Hypercalcemia | 0 | 0 |
| Hyperglycemia | 0 | 1 |
| Hyperkalemia | 0 | 0 |
| Hypermagnesemia | 0 | 0 |
| Hypernatremia | 0 | 0 |
| Hypoalbuminemia | 0 | 0 |
| Hypocalcemia | 0 | 0 |
| Hypoglycemia | 0 | 0 |
| Hypokalemia | 0 | 0 |
| Hypomagnesemia | 0 | 0 |
| Hyponatremia | 1 | 1 |
| Hypophosphatemia | 0 | 1 |
| nanograms/milliliter (ng/mL) | Crizotinib + Pembrolizumab |
|---|---|
| Day 1 of Cycle 1: pre-dose | 0 (0 to 0) |
| Day 1 of Cycle 2: pre-dose | 379 (379 to 379) |
| Day 1 of Cycle 4: pre-dose | 147 (147 to 147) |
| Day 1 of Cycle 6: pre-dose | 235 (235 to 235) |
| Day 1 of Cycle 8: pre-dose | 257 (257 to 257) |
| End of treatment | 166.04 (8.08 to 324) |
| ng/mL | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|
| Day 15 of monotherapy: pre-dose | 273 (79.9 to 531) |
| Day 15 of monotherapy: 1 hour post-dose | 262.5 (191 to 300) |
| Day 15 of monotherapy: 2 hours post-dose | 345 (159 to 455) |
| Day 15 of monotherapy: 4 hours post-dose | 331 (133 to 375) |
| Day 15 of monotherapy: 6 hours post-dose | 278 (115 to 373) |
| Day 15 of monotherapy: 8 hours post-dose | 294.5 (129 to 382) |
| Day 1 of Cycle 1: pre-dose | 272.5 (176 to 337) |
| Day 1 of Cycle 2: pre-dose | 131 (0.842 to 249) |
| Day 1 of Cycle 4: pre-dose | 194.5 (37.5 to 352) |
| Day 1 of Cycle 6: pre-dose | 249 (175 to 311) |
| Day 1 of Cycle 6: 1 hour post-dose | 272 (184 to 281) |
| Day 1 of Cycle 6: 2 hours post-dose | 274 (194 to 497) |
| Day 1 of Cycle 6: 4 hours post-dose | 317 (198 to 450) |
| Day 1 of Cycle 6: 6 hours post-dose | 301 (172 to 369) |
| Day 1 of Cycle 6: 8 hours post-dose | 229.5 (173 to 367) |
| Day 1 of Cycle 8: pre-dose | 244.5 (159 to 285) |
| End of treatment | 24.65 (0.65 to 489) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
| ng/mL | Crizotinib + Pembrolizumab |
|---|---|
| Day 1 of Cycle 1: pre-dose | 0 (0 to 0) |
| Day 1 of Cycle 2: pre-dose | 182 (182 to 182) |
| Day 1 of Cycle 4: pre-dose | 46.4 (46.4 to 46.4) |
| Day 1 of Cycle 6: pre-dose | 99.1 (99.1 to 99.1) |
| Day 1 of Cycle 8: pre-dose | 67 (67 to 67) |
| End of treatment | 56.58 (2.16 to 111) |
PF-06260182 is a metabolite of crizotinib.
| ng/mL | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|
| Day 15 of monotherapy: pre-dose | 91.35 (28.4 to 148) |
| Day 15 of monotherapy: 1 hour post-dose | 74.15 (46.8 to 93.9) |
| Day 15 of monotherapy: 2 hours post-dose | 84.3 (52.3 to 141) |
| Day 15 of monotherapy: 4 hours post-dose | 107 (53.3 to 117) |
| Day 15 of monotherapy: 6 hours post-dose | 91.85 (45.8 to 105) |
| Day 15 of monotherapy: 8 hours post-dose | 84.5 (42.5 to 129) |
| Day 1 of Cycle 1: pre-dose | 83.2 (40.3 to 107) |
| Day 1 of Cycle 2: pre-dose | 21.6 (0 to 65.1) |
| Day 1 of Cycle 4: pre-dose | 61.3 (8.55 to 98.3) |
| Day 1 of Cycle 6: pre-dose | 74.5 (30.1 to 94.1) |
| Day 1 of Cycle 6: 1 hour post-dose | 69.8 (30.8 to 80.6) |
| Day 1 of Cycle 6: 2 hours post-dose | 65.8 (40.8 to 144) |
| Day 1 of Cycle 6: 4 hours post-dose | 73.3 (31.4 to 158) |
| Day 1 of Cycle 6: 6 hours post-dose | 77.7 (38.2 to 139) |
| Day 1 of Cycle 6: 8 hours post-dose | 60.6 (38.4 to 111) |
| Day 1 of Cycle 8: pre-dose | 62.75 (32.1 to 83.9) |
| End of treatment | 2.75 (0 to 112) |
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
No measurements were reported for this outcome.
PF-06260182 is a metabolite of crizotinib.
| ratio | Crizotinib + Pembrolizumab |
|---|---|
| Day 1 of Cycle 2: pre-dose | 0.480 (0.480 to 0.480) |
| Day 1 of Cycle 4: pre-dose | 0.316 (0.316 to 0.316) |
| Day 1 of Cycle 6: pre-dose | 0.422 (0.422 to 0.422) |
| Day 1 of Cycle 8: pre-dose | 0.261 (0.261 to 0.261) |
| End of treatment | 0.305 (0.267 to 0.343) |
PF-06260182 is a metabolite of crizotinib.
| ratio | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|
| Day 15 of monotherapy: pre-dose | 0.334 (0.274 to 0.401) |
| Day 15 of monotherapy: 1 hour post dose | 0.275 (0.226 to 0.367) |
| Day 15 of monotherapy: 2 hours post dose | 0.307 (0.185 to 0.365) |
| Day 15 of monotherapy: 4 hours post dose | 0.321 (0.275 to 0.401) |
| Day 15 of monotherapy: 6 hours post dose | 0.330 (0.268 to 0.398) |
| Day 15 of monotherapy: 8 hours post dose | 0.311 (0.263 to 0.338) |
| Day 1 of Cycle 1: pre-dose | 0.311 (0.229 to 0.376) |
| Day 1 of Cycle 2: pre-dose | 0.217 (0 to 0.303) |
| Day 1 of Cycle 4: pre-dose | 0.293 (0.228 to 0.355) |
| Day 1 of Cycle 6: pre-dose | 0.258 (0.172 to 0.361) |
| Day 1 of Cycle 6: 1 hour post dose | 0.249 (0.145 to 0.287) |
| Day 1 of Cycle 6: 2 hours post dose | 0.239 (0.210 to 0.290) |
| Day 1 of Cycle 6: 4 hours post dose | 0.231 (0.159 to 0.351) |
| Day 1 of Cycle 6: 6 hours post dose | 0.258 (0.219 to 0.406) |
| Day 1 of Cycle 6: 8 hours post dose | 0.264 (0.212 to 0.302) |
| Day 1 of Cycle 8: pre-dose | 0.244 (0.202 to 0.323) |
| End of treatment | 0.105 (0 to 0.229) |
| ng/mL | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Day 1 of Cycle 1: pre-dose | 0 (0 to 0) | 0 (0 to 0) |
| Day 1 of Cycle 1: end of infusion | 63150 (38300 to 88000) | 61400 (34600 to 102000) |
| Day 8 of Cycle 1: 120 hours post Day 1 dosing | 25550 (20600 to 30500) | 26800 (19100 to 31900) |
| Day 15 of Cycle 1: 336 hours post Day 1 dosing | 19600 (14800 to 24400) | 20100 (11000 to 23700) |
| Day 1 of Cycle 2: pre-dose | 9840 (8680 to 11000) | 15750 (8020 to 19600) |
| Day 1 of Cycle 4: pre-dose | — | 31600 (18200 to 37300) |
| Day 1 of Cycle 6: pre-dose | — | 37000 (28500 to 64000) |
| Day 1 of Cycle 8: pre-dose | — | 38800 (26600 to 64500) |
| Day 1 of Cycle 8: end of infusion | — | 14300 (11700 to 14500) |
| Day 1 of Cycle 12: pre-dose | — | 99350 (85700 to 113000) |
| Day 1 of Cycle 16: pre-dose | — | 29300 (29300 to 29300) |
| End of treatment | 10800 (10800 to 10800) | 27500 (3370 to 45800) |
Archived formalin-fixed, paraffin-embedded tumor issue block was collected at screening. PD-L1 assessment was performed using immunohistochemistry. A sample was considered negative if tumor proportion score was less than 1%; positive if tumor proportion score was greater than or equal to 1%; strong positive if tumor proportion score was greater than or equal to 50%.
| Participants | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| Negative | 1 | 1 |
| Positive | 1 | 3 |
| Strong positive | 0 | 2 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crizotinib + Pembrolizumab | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| PneumoniaInfections and infestations | 1/2 | 0/7 |
| Alanine aminotransferase increasedInvestigations | 1/2 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 1/2 | 1/7 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/2 | 0/7 |
| Event | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab |
|---|---|---|
| PyrexiaGeneral disorders | 2/2 | 0/7 |
| Alanine aminotransferase increasedInvestigations | 2/2 | 6/7 |
| Aspartate aminotransferase increasedInvestigations | 2/2 | 5/7 |
| DysgeusiaNervous system disorders | 2/2 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 5/7 |
| NauseaGastrointestinal disorders | 1/2 | 5/7 |
| Acute myocardial infarctionCardiac disorders | 1/2 | 0/7 |
| Atrial fibrillationCardiac disorders | 1/2 | 0/7 |
| TachycardiaCardiac disorders | 1/2 | 0/7 |
| Visual impairmentEye disorders | 1/2 | 3/7 |
Baseline analysis population included all participants enrolled in this study.
| Age, Continuous(years) | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Total |
|---|---|---|---|
| Mean | 64.5 ± 12 | 56.4 ± 13 | 58.2 ± 12.6 |
| Sex: Female, Male(Participants) | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 1 | 4 | 5 |
| Race/Ethnicity, Customized(Participants) | Crizotinib + Pembrolizumab | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Total |
|---|---|---|---|
| White | 2 | 5 | 7 |
| Asian | 0 | 1 | 1 |
| Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2015 to primary completion in Dec 2017, 26 months.
Results were first posted in Jul 2019, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib
Carcinoma, Non-Small-Cell Lung →